Impact of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors on Nocturnal Polyuria: A Cross-Sectional Study.

AIM

The aim of this study was to investigate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on nocturnal polyuria. Additionally, this study aimed to compare the short-acting SGLT2 inhibitor tofogliflozin and other SGLT2 inhibitors.

METHODS

A questionnaire was administered to 142 patients undergoing treatment for type 2 diabetes to assess the presence of nocturnal polyuria.

RESULTS

Among the 69 patients not taking SGLT2 inhibitors (Non-SGLT2-I Group), 41 (59.4%) reported no nocturnal polyuria, while 28 (40.6%) reported its presence. In contrast, among the 73 patients taking SGLT2 inhibitors (SGLT2-I Group), 34 (46.6%) reported no nocturnal polyuria, whereas 39 (53.4%) reported it. Further categorization of the SGLT2-I Group into those taking tofogliflozin (Tofo Group, 23 patients) and those using other SGLT2 inhibitors (Other SGLT2-I Group, 50 patients) revealed the following: In the Tofo Group, 15 (65.2%) patients reported no nocturnal polyuria, while eight (34.8%) did. In the Other SGLT2-I Group, 19 (38%) patients reported no nocturnal polyuria, while 31 (62%) reported it. A comparison between the Non-SGLT2-I and the Other SGLT2-I groups showed a significantly higher occurrence of nocturnal polyuria in the latter (p = 0.026). Furthermore, in the comparison between the Tofo Group and the Other SGLT2-I Group, the latter showed a significantly higher incidence of nocturnal polyuria (p = 0.043).

CONCLUSIONS

Tofogliflozin is less likely to exacerbate nocturnal polyuria compared to other SGLT2 inhibitors.